Comparative Efficacy of PCSK9 inhibitors, Olpasiran and Zerlasiran in Reducing Lipoprotein(a) Levels: A Network Meta-Analysis of Clinical Trials

This network meta-analysis aims to compare the efficacy of PCSK9 inhibitors, Olpasiran and Zerlasiran in reducing Lipoprotein(a) levels. By systematically reviewing and synthesizing data from various clinical trials, the study evaluates key outcomes such as the magnitude and consistency of Lipoprotein(a) reduction. This analysis evaluates the effectiveness of these treatments, providing insights to support clinical decisions and future research on managing elevated Lipoprotein(a) levels.